TY - T1的间歇tuberculo方案sis treatment: Back to the Future? JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.02510-2020 VL - 56 IS - 3 SP - 2002510 AU - Alffenaar, Jan-Willem C. AU - Tiberi, Simon AU - Cirillo, Daniela M. AU - Migliori, Giovanni Battista Y1 - 2020/09/01 UR - //www.qdcxjkg.com/content/56/3/2002510.abstract N2 - Despite all efforts to accelerate the response against tuberculosis (TB), many countries are struggling to achieve the milestones of the End TB strategy [1]. The investment required in a strong healthcare system to combat TB is significant. Lack of a short and highly active sterilising TB treatment regimen is the main reason for treatment failure and emergence of drug resistance [2]. With increasing drug resistance, the treatment becomes longer and more difficult to manage due to use of more toxic and less active drugs. Although treatment management is focused on prevention of adverse drug reactions, most patients will experience drug toxicity during treatment [3] which can result in nonadherence.Once weekly bedaquiline, rifapentine and pyrazinamide has sterilising activity and is ready for further exploration in a clinical trial, including appropriate safety and pharmacokinetic assessment https://bit.ly/3ivrY4mThe project is part of the activities of the Global Tuberculosis Network (GTN) and of the WHO Collaborating Centre for Tuberculosis and Lung Diseases, Tradate, ITA-80, 2017-2020- GBM/RC/LDA. The authors wish to thank Anne-Grete Märtson for her editorial assistance and for preparing the artwork for figure 1. ER -